PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	trastuzumab + pertuzumab + alpelisib Sensitive: B - Late Trials AACR 2023 - 2 weeks (New B) trastuzumab + pertuzumab + alpelisib Sensitive : B AACR 2023 - 2wk	trastuzumab + pertuzumab + alpelisib Sensitive: B - Late Trials AACR 2023 - 2 weeks trastuzumab + pertuzumab + alpelisib Sensitive : B AACR 2023 - 2 weeks - (New B)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	TC Sensitive: C3 – Early Trials SG-BCC 2023 - 2 weeks (New C3) TC Sensitive : C3 SG-BCC 2023 - 2wk	TC Sensitive: C3 – Early Trials SG-BCC 2023 - 2 weeks TC Sensitive : C3 SG-BCC 2023 - 2 weeks - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	VERU-111 Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) VERU-111 Sensitive : D AACR 2023 - 2wk	VERU-111 Sensitive: D – Preclinical AACR 2023 - 2 weeks VERU-111 Sensitive : D AACR 2023 - 2 weeks - (New D)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	TH 1902 Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) TH 1902 Sensitive : D AACR 2023 - 2wk	TH 1902 Sensitive: D – Preclinical AACR 2023 - 2 weeks TH 1902 Sensitive : D AACR 2023 - 2 weeks - (New D)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab-IFN-β mutein Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) trastuzumab-IFN-β mutein Sensitive : D AACR 2023 - 2wk	trastuzumab-IFN-β mutein Sensitive: D – Preclinical AACR 2023 - 2 weeks trastuzumab-IFN-β mutein Sensitive : D AACR 2023 - 2 weeks - (New D)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	D3L-001 Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) D3L-001 Sensitive : D AACR 2023 - 2wk	D3L-001 Sensitive: D – Preclinical AACR 2023 - 2 weeks D3L-001 Sensitive : D AACR 2023 - 2 weeks - (New D)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pertuzumab + D3L-001 Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) pertuzumab + D3L-001 Sensitive : D AACR 2023 - 2wk	pertuzumab + D3L-001 Sensitive: D – Preclinical AACR 2023 - 2 weeks pertuzumab + D3L-001 Sensitive : D AACR 2023 - 2 weeks - (New D)
CD47 positive	HER2 Positive Breast Cancer	CD47 positive	HER2 Positive Breast Cancer	D3L-001 Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) D3L-001 Sensitive : D AACR 2023 - 2wk	D3L-001 Sensitive: D – Preclinical AACR 2023 - 2 weeks D3L-001 Sensitive : D AACR 2023 - 2 weeks - (New D)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab-pkrb Sensitive: B - Late Trials BioDrugs - 3 weeks (New B) trastuzumab-pkrb Sensitive : B BioDrugs - 3wk	trastuzumab-pkrb Sensitive: B - Late Trials BioDrugs - 3 weeks trastuzumab-pkrb Sensitive : B BioDrugs - 3 weeks - (New B)
IL6 elevation	HER2 Positive Breast Cancer	IL6 elevation	HER2 Positive Breast Cancer	trastuzumab Sensitive: C3 – Early Trials Altern Ther Health Med - 3 weeks (New C3) trastuzumab Sensitive : C3 Altern Ther Health Med - 3wk	trastuzumab Sensitive: C3 – Early Trials Altern Ther Health Med - 3 weeks trastuzumab Sensitive : C3 Altern Ther Health Med - 3 weeks - (New C3)
TNFA elevation	HER2 Positive Breast Cancer	TNFA elevation	HER2 Positive Breast Cancer	trastuzumab Sensitive: C3 – Early Trials Altern Ther Health Med - 3 weeks (New C3) trastuzumab Sensitive : C3 Altern Ther Health Med - 3wk	trastuzumab Sensitive: C3 – Early Trials Altern Ther Health Med - 3 weeks trastuzumab Sensitive : C3 Altern Ther Health Med - 3 weeks - (New C3)
IL18 elevation	HER2 Positive Breast Cancer	IL18 elevation	HER2 Positive Breast Cancer	trastuzumab Sensitive: C3 – Early Trials Altern Ther Health Med - 3 weeks (New C3) trastuzumab Sensitive : C3 Altern Ther Health Med - 3wk	trastuzumab Sensitive: C3 – Early Trials Altern Ther Health Med - 3 weeks trastuzumab Sensitive : C3 Altern Ther Health Med - 3 weeks - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	ARX788 Sensitive: B - Late Trials Businesswire - 4 weeks (New B) ARX788 Sensitive : B Businesswire - 4wk	ARX788 Sensitive: B - Late Trials Businesswire - 4 weeks ARX788 Sensitive : B Businesswire - 4 weeks - (New B)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	margetuximab Sensitive: A1 - Approval margetuximab Sensitive : A1	margetuximab Sensitive: A1 - Approval margetuximab Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: A1 - Approval ado-trastuzumab emtansine Sensitive : A1	ado-trastuzumab emtansine Sensitive: A1 - Approval ado-trastuzumab emtansine Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval pertuzumab / trastuzumab / hyaluronidase-zzxf Sensitive : A1	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval pertuzumab / trastuzumab / hyaluronidase-zzxf Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1	trastuzumab-pkrb Sensitive: A1 - Approval trastuzumab-pkrb Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval Zercepac (trastuzumab biosimilar) Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	THP Sensitive: A2 - Guideline THP Sensitive : A2	THP Sensitive: A2 - Guideline THP Sensitive : A2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	TCHP Sensitive: A2 - Guideline TCHP Sensitive : A2	TCHP Sensitive: A2 - Guideline TCHP Sensitive : A2
ER positive	HER2 Positive Breast Cancer	ER positive	HER2 Positive Breast Cancer	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + abemaciclib Sensitive: A2 - Guideline trastuzumab + abemaciclib Sensitive : A2	trastuzumab + abemaciclib Sensitive: A2 - Guideline trastuzumab + abemaciclib Sensitive : A2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	TCH Sensitive: A2 - Guideline TCH Sensitive : A2	TCH Sensitive: A2 - Guideline TCH Sensitive : A2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2

HER2 Positive Breast Cancer

Associations(425)

Associations
(425)